May 8 - 9 Biotech & Pharma Updates

All your Biotech & Pharma news in one daily email

Welcome to the TLDR Biotech newsletter!

Our aim is to be your one-stop source for biotech and pharma updates - all with one daily email.

We’re always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), we’d love to hear from you!

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

  • THE GOOD - good news (eg. fundraises, product approvals)

  • THE BAD - negative news (eg. clinical trial failures, layoffs)

  • THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

  • Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

  • There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

⬇️ The Good News ⬇️

THE GOOD
Approvals

Sobi (Swedish Orphan Biovitrum) scores earlier use label expansion
Peptide, paroxysmal nocturnal haemoglobinuria, label expansion - Read more

THE GOOD
Business Development

Royalty Pharma pays $525M for milestone and royalty from Sanofi-partnered asset
Antibody, multiple sclerosis - Read more

THE GOOD
Clinical Trials

Innovent flaunts Phase 3 diabetes win
GLP-1, obesity, diabetes - Read more

Freeline reports positive mid-stage Ph1/2 results
Gene therapy, Gaucher’s - Read more

THE GOOD
Company Launch

Commit Biologics launches with $17.2M
Antibody, cancer, autoimmune - Read more 

THE GOOD
Fundraises

ArkeaBio, $26.5M Series A
Ag-biotech, ruminant vaccine - Read more

Rad AI scores rad $50M Series B
Radiology, AI - Read more

Attovia Therapeutics, $105M Series B
Biologics, immunology, inflammation - Read more

Aardvark Therapeutics, $85M Series C (oversubscribed)
Small molecule, Prader-Willi syndrome - Read more

Bluejay Therapeutics, $182M Series C
Antibody, chronic hepatitis D (HDV) - Read more

Verona secures (up to) $650M financing deal
Small molecule, COPD - Read more

Ennogen lands £30M ($37.5M) credit facility
Heritage brands, medical device - Read more

GHIT Fund invests JP¥1.64B ($10.8M)
Malaria, neglected tropical diseases - Read more

THE GOOD
IPO

Oranovo Holdings prices IPO
$0.80 offering, $5.25M total raise expected
Small molecule, IBS, cancer - Read more

THE GOOD
Mergers & Acquisitions

American Clinical Research Service buys Elixia
Deal terms not disclosed
Clinical trial services, CRO - Read more

Samsung Medison buys Sonio for $92.7M (₩126B)
Medical device, AI, ultrasound - Read more

THE GOOD
Opinions

Informed consent key to increasing diversity in clinical trial participants - Read more

THE GOOD
Partnerships

Novo Nordisk signs (up to) $600M drug discovery pact with Metaphore Biotechnologies
Drug discovery, obesity - Read more

Minaris Regenerative Medicine goes officially commercial with bluebird bio partnership milestone
Manufacturing, gene therapy, sickle cell - Read more 

THE GOOD
Patient Access

bluebird bio announces 15 new gene therapy patients, stock jumps
Gene therapy, sickle cell, thalassemia - Read more

THE GOOD
Politics & Policy

FDA releases new regulatory plans for biotech - Read more

DMD newborn screening inclusion postponed but still on the table
Genetic screening, Duchenne’s - Read more

THE GOOD
Strategic Plans

Regeneron cell med chief has the “secret sauce”
Cell therapy - Read more

Monopar Therapeutics goes full send on radiopharma
Radiopharmaceuticals, company pivot - Read more

⬇️ The Bad News ⬇️

THE BAD
Clinical Trials

After clinical holds, Rapt Therapeutics shutters two Phase 2 trials
Small molecule, atopic dermatitis - Read more

THE BAD
Layoffs

Pfizer cuts 74 jobs from Seagen acquisition
Antibody, ADC - Read more

THE BAD
Site Closure

Takeda to shutter San Diego R&D site, 340 jobs - Read more

THE BAD
Strategic Plans

RallyBio stops investing in preclinical assets, looking to offload
Antibody, iron overload - Read more

⬇️ The Ugly News ⬇️

THE UGLY
Drug Pricing

Not cost-effective - ICER on $250k annually for Geron’s anemia treatment
Anemia, synthetic conjugate - Read more

THE UGLY
Lawsuits

We got the patents, so time to sue - AstraZeneca, Merck & Co.
Small molecule, cancer - Read more

THE UGLY
Politics & Policy

Lawmakers propose expiry dates on China-based pharma contracts
Geopolitics, USA-China relations - Read more

According to BIO, sudden US-China biopharma severance could harm millions of patients
Geopolitics, USA-China relations - Read more

THE UGLY
Recalls

After multiple issues and recalls, FDA warns against Getinge
Medical device, cardiovascular - Read more

THE UGLY
Reputation

Novartis file snafu brings “discredit on the industry” - Read more

DEEP DIVES & HOT TAKES
Pharma is facing a $200B patent cliff

Mad Man Images GIF by getflexseal

As we approach 2030, expiring patents will cost the pharma industry more than $200 billion in annual revenue.

What to know who’s going to feel it, and by how much?

Lucky for you, there’s a handy visual timeline for just this topic, covering the 30 most valuable drugs according to 2023 sales.

You’re all caught up on the latest Pharma & Biotech News!

Its Friday GIF by Nebraska Humane Society

Gif by nehumanesociety on Giphy

We want to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send us an email - we want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍